ID   LN-443
AC   CVCL_3960
SY   LN 443; LN443
DR   BTO; BTO:0004449
DR   BioGRID_ORCS_Cell_line; 407
DR   BioSample; SAMN03151823
DR   BioSample; SAMN10988388
DR   cancercelllines; CVCL_3960
DR   Cell_Model_Passport; SIDM01371
DR   Cosmic; 849871
DR   Cosmic; 2367496
DR   Cosmic; 2516031
DR   DepMap; ACH-000673
DR   PharmacoDB; LN443_847_2019
DR   Wikidata; Q54902784
RX   PubMed=7693337;
RX   PubMed=8509230;
RX   PubMed=10416987;
RX   PubMed=20593219;
RX   PubMed=22570425;
RX   PubMed=25984343;
RX   PubMed=30894373;
RX   PubMed=31068700;
CC   Problematic cell line: Contaminated. Shown to be a LN-444 derivative (PubMed=22570425). Originally thought to originate from a 66 year old male patient with a glioblastoma at the right fronto-temporal lobe.
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00451.
CC   Population: Caucasian.
CC   Doubling time: 40 hours (PubMed=25984343).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His214Arg (c.641A>G); ClinVar=VCV000376615; Zygosity=Homozygous (DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: shRNA library screening.
CC   Genome ancestry: African=3.39%; Native American=0%; East Asian, North=4.23%; East Asian, South=0%; South Asian=4.37%; European, North=27.1%; European, South=60.91% (PubMed=30894373).
CC   Derived from site: In situ; Brain, left parietal lobe; UBERON=UBERON_0002802.
ST   Source(s): PubMed=22570425
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 8
ST   D16S539: 10,11
ST   D18S51: 15,16
ST   D21S11: 28,30
ST   D3S1358: 15,17
ST   D5S818: 9,12
ST   D7S820: 10
ST   D8S1179: 13,14
ST   FGA: 21,23
ST   Penta D: 11,12
ST   Penta E: 7,13
ST   TH01: 7,9
ST   TPOX: 8
ST   vWA: 18,19
DI   NCIt; C3058; Glioblastoma
DI   ORDO; Orphanet_360; Glioblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_3961 ! LN-444
SX   Female
AG   48Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 27
RX   PubMed=7693337;
RA   Li H., Hamou M.-F., de Tribolet N., Jaufeerally R., Hofmann M.,
RA   Diserens A.-C., Van Meir E.G.;
RT   "Variant CD44 adhesion molecules are expressed in human brain
RT   metastases but not in glioblastomas.";
RL   Cancer Res. 53:5345-5349(1993).
RX   PubMed=8509230; DOI=10.1002/ijc.2910540329;
RA   Rimoldi D., Romero P., Carrel S.;
RT   "The human melanoma antigen-encoding gene, MAGE-1, is expressed by
RT   other tumour cells of neuroectodermal origin such as glioblastomas and
RT   neuroblastomas.";
RL   Int. J. Cancer 54:527-528(1993).
RX   PubMed=10416987; DOI=10.1111/j.1750-3639.1999.tb00536.x;
RA   Ishii N., Maier D., Merlo A., Tada M., Sawamura Y., Diserens A.-C.,
RA   Van Meir E.G.;
RT   "Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor
RT   suppressor genes in human glioma cell lines.";
RL   Brain Pathol. 9:469-479(1999).
RX   PubMed=20593219; DOI=10.1007/s11060-010-0283-9;
RA   Blough M.D., Beauchamp D.C., Westgate M.R., Kelly J.J.P.,
RA   Cairncross J.G.;
RT   "Effect of aberrant p53 function on temozolomide sensitivity of glioma
RT   cell lines and brain tumor initiating cells from glioblastoma.";
RL   J. Neurooncol. 102:1-7(2011).
RX   PubMed=22570425; DOI=10.1093/neuonc/nos072;
RA   Bady P., Diserens A.-C., Castella V., Kalt S., Heinimann K.,
RA   Hamou M.-F., Delorenzi M., Hegi M.E.;
RT   "DNA fingerprinting of glioma cell lines and considerations on
RT   similarity measurements.";
RL   Neuro-oncol. 14:701-711(2012).
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035-140035(2014).
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).